These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19053885)

  • 1. The use of copper-lowering therapy with tetrathiomolybdate in medicine.
    Brewer GJ
    Expert Opin Investig Drugs; 2009 Jan; 18(1):89-97. PubMed ID: 19053885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
    Brewer GJ
    Metallomics; 2009; 1(3):199-206. PubMed ID: 21305118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation.
    Brewer GJ
    J Cell Mol Med; 2003; 7(1):11-20. PubMed ID: 12767257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The promise of copper lowering therapy with tetrathiomolybdate in the cure of cancer and in the treatment of inflammatory disease.
    Brewer GJ
    J Trace Elem Med Biol; 2014 Oct; 28(4):372-8. PubMed ID: 25194954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of lowering copper levels with tetrathiomolybdate and zinc on mouse tumor and doxorubicin models.
    Hou G; Dick R; Zeng C; Brewer GJ
    Transl Res; 2006 Dec; 148(6):309-14. PubMed ID: 17162252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer.
    Brewer GJ
    Curr Cancer Drug Targets; 2005 May; 5(3):195-202. PubMed ID: 15892619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis.
    Hou G; Abrams GD; Dick R; Brewer GJ
    Transl Res; 2008 Nov; 152(5):239-44. PubMed ID: 19010295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
    Brewer GJ; Merajver SD
    Integr Cancer Ther; 2002 Dec; 1(4):327-37. PubMed ID: 14664727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease.
    Brewer GJ
    Exp Biol Med (Maywood); 2001 Jul; 226(7):665-73. PubMed ID: 11444102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
    Brewer GJ; Askari F; Dick RB; Sitterly J; Fink JK; Carlson M; Kluin KJ; Lorincz MT
    Transl Res; 2009 Aug; 154(2):70-7. PubMed ID: 19595438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticopper therapy against cancer and diseases of inflammation and fibrosis.
    Brewer GJ
    Drug Discov Today; 2005 Aug; 10(16):1103-9. PubMed ID: 16182195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor and antiinflammatory effects of tetrathiotungstate in comparison with tetrathiomolybdate.
    Hou G; Dick R; Zeng C; Brewer GJ
    Transl Res; 2007 May; 149(5):260-4. PubMed ID: 17466925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm.
    Khan G; Merajver S
    Expert Opin Investig Drugs; 2009 Apr; 18(4):541-8. PubMed ID: 19335282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.
    Brewer GJ; Dick RD; Grover DK; LeClaire V; Tseng M; Wicha M; Pienta K; Redman BG; Jahan T; Sondak VK; Strawderman M; LeCarpentier G; Merajver SD
    Clin Cancer Res; 2000 Jan; 6(1):1-10. PubMed ID: 10656425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients.
    Brewer GJ; Dick RD; Johnson V; Wang Y; Yuzbasiyan-Gurkan V; Kluin K; Fink JK; Aisen A
    Arch Neurol; 1994 Jun; 51(6):545-54. PubMed ID: 8198464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetrathiomolybdate, a copper chelator inhibited imiquimod-induced skin inflammation in mice.
    Hsu PY; Yen HH; Yang TH; Su CC
    J Dermatol Sci; 2018 Oct; 92(1):30-37. PubMed ID: 30126748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical recommendations and new therapies for Wilson's disease.
    Brewer GJ
    Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetrathiomolybdate causes formation of hepatic copper-molybdenum clusters in an animal model of Wilson's disease.
    George GN; Pickering IJ; Harris HH; Gailer J; Klein D; Lichtmannegger J; Summer KH
    J Am Chem Soc; 2003 Feb; 125(7):1704-5. PubMed ID: 12580588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in dissolution of liver fibrosis in an animal model by tetrathiomolybdate.
    Hou G; Dick R; Brewer GJ
    Exp Biol Med (Maywood); 2009 Jun; 234(6):662-5. PubMed ID: 19307461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetrathiomolybdate inhibits the reaction of cisplatin with human copper chaperone Atox1.
    Tian Y; Fang T; Yuan S; Zheng Y; Arnesano F; Natile G; Liu Y
    Metallomics; 2018 May; 10(5):745-750. PubMed ID: 29721562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.